Vertex并未停止Nav1.8抑制剂的开发。根据Vertex最新公开资料,一方面在着手拓展VX-548新的适应症--糖尿病周围神经病变(DPN,Phase II,突破性疗法);腰骶神经根病(LSR,Phase II);另一方面Vertex也在积极布局第三代的Nav1.8抑制剂VX-993以及VX973已经开始了临床I期的研究。VX-993/973会在药效和PK等方面进一步改善。在...
VX-548 Phase 3 Results in Patients Undergoing Bunionectomy Efficacy Results Patients aged 18 to 80 years with moderate or severe pain after bunionectomy surgery were eligible to participate in the trial. 1,073 patients were randomized and dosed with either VX-548 administered orally with an initia...
- VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy Designation granted by FDA - BOSTON--(BUSINESS WIRE)--Ju...
Food and Drug Administration (FDA), Vertex plans to advance the selective NaV1.8 inhibitor VX-548 into Phase 3 clinical trials in the fourth quarter of 2022. Vertex also intends to initiate a Phase 2 dose-ranging study of VX-548 in neuropathic pain by the end of this year. In addition,...
根据Vertex最新公开资料,一方面在着手拓展VX-548新的适应症--糖尿病周围神经病变(DPN,Phase II,突破性疗法);腰骶神经根病(LSR,Phase II);另一方面Vertex也在积极布局第三代的Nav1.8抑制剂VX-993以及VX973已经开始了临床I期的研究。VX-993/973会在药效和PK等方面进一步改善。在2024年1月份 J.P. MORGAN HEALTH...
根据Vertex最新公开资料,一方面在着手拓展VX-548新的适应症--糖尿病周围神经病变(DPN,Phase II,突破性疗法);腰骶神经根病(LSR,Phase II);另一方面Vertex也在积极布局第三代的Nav1.8抑制剂VX-993以及VX973已经开始了临床I期的研究。VX-993/973会在药效和PK等方面进一步改善。在2024年1月份 J.P. MORGAN HEALTH...
The efficacy and safety of VX-548 in the treatment of acute pain was demonstrated in two Phase II and two Phase III clinical trials. Table 1 summarizes the characteristics of each trial, while Table 2 highlights the key findings. Table 1. Summary of Phase II and III trial characteristics. ...
Vertex Pharmaceuticals Incorporated today announced that it has begun a Phase 2 proof-of-concept (POC) study in acute pain following bunionectomy surgery with the selective NaV1.8 inhibitor VX-548 and that it expects to commence a second Phase 2 study in
Vertex Advances VX-548 in Acute and Neuropathic Pain July 22, 2022 - VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy ...
VX-548 Phase 3 Results in Patients Undergoing Bunionectomy Efficacy Results Patients aged 18 to 80 years with moderate or severe pain after bunionectomy surgery were eligible to participate in the trial. 1,073 patients were randomized and dosed with either VX-548 administered orally with ...